Capital Asset Advisory Services LLC Sells 89 Shares of PerkinElmer, Inc. (NYSE:PKI)

Capital Asset Advisory Services LLC trimmed its holdings in shares of PerkinElmer, Inc. (NYSE:PKIGet Rating) by 5.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,418 shares of the medical research company’s stock after selling 89 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in PerkinElmer were worth $285,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Toronto Dominion Bank boosted its stake in PerkinElmer by 31.9% in the 4th quarter. Toronto Dominion Bank now owns 71,529 shares of the medical research company’s stock worth $14,382,000 after purchasing an additional 17,309 shares during the period. Mackay Shields LLC boosted its position in shares of PerkinElmer by 10.0% during the fourth quarter. Mackay Shields LLC now owns 18,704 shares of the medical research company’s stock worth $3,761,000 after buying an additional 1,700 shares during the period. Empirical Finance LLC grew its stake in shares of PerkinElmer by 38.5% during the 4th quarter. Empirical Finance LLC now owns 1,930 shares of the medical research company’s stock worth $388,000 after acquiring an additional 537 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in shares of PerkinElmer by 1.3% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 6,075 shares of the medical research company’s stock valued at $1,221,000 after purchasing an additional 77 shares during the last quarter. Finally, Advisor Group Holdings Inc. lifted its position in shares of PerkinElmer by 8.3% in the fourth quarter. Advisor Group Holdings Inc. now owns 23,399 shares of the medical research company’s stock worth $4,703,000 after purchasing an additional 1,795 shares in the last quarter. Hedge funds and other institutional investors own 81.95% of the company’s stock.

Shares of PKI traded down $1.04 during midday trading on Monday, reaching $160.38. The stock had a trading volume of 11,890 shares, compared to its average volume of 874,161. The firm has a market cap of $20.23 billion, a PE ratio of 19.73, a P/E/G ratio of 0.50 and a beta of 1.10. The firm has a 50 day simple moving average of $175.18 and a 200-day simple moving average of $178.37. PerkinElmer, Inc. has a one year low of $126.75 and a one year high of $203.16. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.70.

PerkinElmer (NYSE:PKIGet Rating) last posted its quarterly earnings results on Tuesday, February 1st. The medical research company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.41. The business had revenue of $1.36 billion during the quarter, compared to analysts’ expectations of $1.32 billion. PerkinElmer had a return on equity of 23.73% and a net margin of 18.40%. PerkinElmer’s quarterly revenue was up .7% on a year-over-year basis. During the same quarter last year, the company posted $3.96 earnings per share. As a group, research analysts forecast that PerkinElmer, Inc. will post 6.92 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 13th. Investors of record on Friday, April 22nd will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.17%. The ex-dividend date is Thursday, April 21st. PerkinElmer’s dividend payout ratio (DPR) is presently 3.47%.

In related news, insider Daniel R. Tereau sold 6,696 shares of PerkinElmer stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $165.84, for a total transaction of $1,110,464.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.52% of the stock is owned by corporate insiders.

Separately, StockNews.com started coverage on shares of PerkinElmer in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $166.37.

About PerkinElmer (Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

Recommended Stories

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKIGet Rating).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.